Review



human il-4 elispot plus hrp kit  (Mabtech Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Mabtech Inc human il-4 elispot plus hrp kit
    IFN-γ- <t>and</t> <t>IL-4-secreting</t> cells in peripheral blood mononuclear cells stimulated with RBD. Children 3-11 (N=24) and 12-18 years old (N=21) received two doses (on days 0, 28) of SOBERANA 02 and a heterologous third dose (on day 56) of SOBERANA Plus. p value represents the statistic differences as indicated.
    Human Il 4 Elispot Plus Hrp Kit, supplied by Mabtech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+il-4+elispot+plus+hrp+kit/elispot+kit/med_rxiv__2022__03__03__22271313-71-24-30
    Average 90 stars, based on 1 article reviews
    human il-4 elispot plus hrp kit - by Bioz Stars, 2026-09
    90/100 stars

    Images

    1) Product Images from "Open label phase I/II clinical trial and predicted efficacy of SARS-CoV-2 RBD protein vaccines SOBERANA 02 and SOBERANA Plus in children"

    Article Title: Open label phase I/II clinical trial and predicted efficacy of SARS-CoV-2 RBD protein vaccines SOBERANA 02 and SOBERANA Plus in children

    Journal: medRxiv

    doi: 10.1101/2022.03.03.22271313

    IFN-γ- and IL-4-secreting cells in peripheral blood mononuclear cells stimulated with RBD. Children 3-11 (N=24) and 12-18 years old (N=21) received two doses (on days 0, 28) of SOBERANA 02 and a heterologous third dose (on day 56) of SOBERANA Plus. p value represents the statistic differences as indicated.
    Figure Legend Snippet: IFN-γ- and IL-4-secreting cells in peripheral blood mononuclear cells stimulated with RBD. Children 3-11 (N=24) and 12-18 years old (N=21) received two doses (on days 0, 28) of SOBERANA 02 and a heterologous third dose (on day 56) of SOBERANA Plus. p value represents the statistic differences as indicated.

    Techniques Used:

    Related Articles

    other:

    Article Title: Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme
    Article Snippet: RBD-specific T-cell response producing IFN-γ and IL-4 were quantified with enzyme-linked immunospot (ELISpot) assay using human IFN-γ ELISpot PLUS HRP kit (Mabtech, Sweden) and human IL-4 ELISpot plus HRP kit (Mabtech, Sweden) following the manufacturer’s instructions.

    Article Title: Open label phase I/II clinical trial and predicted efficacy of SARS-CoV-2 RBD protein vaccines SOBERANA 02 and SOBERANA Plus in children
    Article Snippet: RBD-specific T-cell response producing IFN-γ and IL-4 were quantified by enzyme-linked immunospot (ELISpot) assay using human IFN-γ ELISpot PLUS HRP kit (Mabtech, Sweden) and human IL-4 ELISpot plus HRP kit (Mabtech, Sweden) following the manufacturer’s instructions.



    Similar Products

    human il-4 elispot plus hrp kit  (Mabtech Inc)
    90
    Mabtech Inc human il-4 elispot plus hrp kit
    IFN-γ- <t>and</t> <t>IL-4-secreting</t> cells in peripheral blood mononuclear cells stimulated with RBD. Children 3-11 (N=24) and 12-18 years old (N=21) received two doses (on days 0, 28) of SOBERANA 02 and a heterologous third dose (on day 56) of SOBERANA Plus. p value represents the statistic differences as indicated.
    Human Il 4 Elispot Plus Hrp Kit, supplied by Mabtech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+il-4+elispot+plus+hrp+kit/elispot+kit/med_rxiv__2022__03__03__22271313-71-24-30
    Average 90 stars, based on 1 article reviews
    human il-4 elispot plus hrp kit - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    IFN-γ- and IL-4-secreting cells in peripheral blood mononuclear cells stimulated with RBD. Children 3-11 (N=24) and 12-18 years old (N=21) received two doses (on days 0, 28) of SOBERANA 02 and a heterologous third dose (on day 56) of SOBERANA Plus. p value represents the statistic differences as indicated.

    Journal: medRxiv

    Article Title: Open label phase I/II clinical trial and predicted efficacy of SARS-CoV-2 RBD protein vaccines SOBERANA 02 and SOBERANA Plus in children

    doi: 10.1101/2022.03.03.22271313

    Figure Lengend Snippet: IFN-γ- and IL-4-secreting cells in peripheral blood mononuclear cells stimulated with RBD. Children 3-11 (N=24) and 12-18 years old (N=21) received two doses (on days 0, 28) of SOBERANA 02 and a heterologous third dose (on day 56) of SOBERANA Plus. p value represents the statistic differences as indicated.

    Article Snippet: RBD-specific T-cell response producing IFN-γ and IL-4 were quantified by enzyme-linked immunospot (ELISpot) assay using human IFN-γ ELISpot PLUS HRP kit (Mabtech, Sweden) and human IL-4 ELISpot plus HRP kit (Mabtech, Sweden) following the manufacturer’s instructions.

    Techniques: